Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Colorcon
Express Scripts
Boehringer Ingelheim
AstraZeneca

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for AF-219


Email this page to a colleague

« Back to Dashboard

What is the drug development status for AF-219?

AF-219 is an investigational drug.

There have been 15 clinical trials for AF-219. The most recent clinical trial was a Phase 2 trial, which was initiated on March 29th 2012.

The most common disease conditions in clinical trials are Cough, Fibrosis, and Pulmonary Fibrosis. The leading clinical trial sponsors are Afferent Pharmaceuticals, Inc., Celerion, and [disabled in preview].

There are twenty-five US patents protecting this investigational drug and two hundred and thirty-three international patents.

Recent Clinical Trials for AF-219
TitleSponsorPhase
A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) FormulationsAfferent Pharmaceuticals, Inc.Phase 1
An 8-Week Refractory Chronic Cough Study (MK-7264-021)Afferent Pharmaceuticals, Inc.Phase 2
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)Afferent Pharmaceuticals, Inc.Phase 2

See all AF-219 clinical trials

Clinical Trial Summary for AF-219

Top disease conditions for AF-219
Top clinical trial sponsors for AF-219

See all AF-219 clinical trials

US Patents for AF-219

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AF-219 ⤷  Sign up for a Free Trial Selective P2X3 modulators BELLUS HEALTH COUGH INC. (Laval, Quebec, CA) NEOMED INSTITUTE (Montreal, Quebec, CA) ⤷  Sign up for a Free Trial
AF-219 ⤷  Sign up for a Free Trial Methods and compositions for treating diseases and conditions Afferent Pharmaceuticals, Inc. (San Mateo, CA) ⤷  Sign up for a Free Trial
AF-219 ⤷  Sign up for a Free Trial JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AF-219

Drugname Country Document Number Estimated Expiration Related US Patent
AF-219 Australia AU2018342751 2037-09-18 ⤷  Sign up for a Free Trial
AF-219 Canada CA3076150 2037-09-18 ⤷  Sign up for a Free Trial
AF-219 China CN111601601 2037-09-18 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Colorcon
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.